@article{HADKE_PETHE_VAIDYA_DEWANI_2022, title={FORMULATION DEVELOPMENT AND CHARACTERIZATION OF LYOPHILIZED FEBUXOSTAT NANOSUSPENSION}, volume={14}, url={https://journals.innovareacademics.in/index.php/ijap/article/view/45614}, DOI={10.22159/ijap.2022v14i6.45614}, abstractNote={<p><strong>Objective: </strong>The study aims to prepare and evaluate febuxostat nanosuspension to improve oral bioavailability.</p> <p><strong>Methods: </strong>Febuxostat nanosuspension was prepared by the solvent-antisolvent method, followed by a lyophilization technique using PVP K-30 as a stabilizer and sodium lauryl sulfate as a surfactant. Drug content, differential scanning calorimetry, powder x-ray diffraction, Fourier transform infrared spectroscopy, and <em>in vitro</em> dissolution studies were used to characterize the nanosuspension.</p> <p><strong>Results: </strong>The results of the characterization studies indicated the formation of nanosuspension. The lyophilized FXT NS particle size is 2170.2 nm, the PDI value is 0.63, the negative zeta potential is 1.6 mV, and the drug content is 19.02%. Functional characterization studies demonstrated that the particle size reduced due to the interaction between the stabilizer and surfactant.</p> <p><strong>Conclusion: </strong>It can be concluded that the prepared febuxostat nanosuspension enhances the aqueous solubility of FXT and improves its oral bioavailability.</p>}, number={6}, journal={International Journal of Applied Pharmaceutics}, author={HADKE, ANKITA and PETHE, ANIL and VAIDYA, SUNITA and DEWANI, SUNIL}, year={2022}, month={Nov.}, pages={91–99} }